MX340402B - Inhibidores triciclicos de cinasas. - Google Patents

Inhibidores triciclicos de cinasas.

Info

Publication number
MX340402B
MX340402B MX2013009873A MX2013009873A MX340402B MX 340402 B MX340402 B MX 340402B MX 2013009873 A MX2013009873 A MX 2013009873A MX 2013009873 A MX2013009873 A MX 2013009873A MX 340402 B MX340402 B MX 340402B
Authority
MX
Mexico
Prior art keywords
kinases
tricyclic inhibitors
compounds
relates
present
Prior art date
Application number
MX2013009873A
Other languages
English (en)
Other versions
MX2013009873A (es
Inventor
Tong Yunsong
D Penning Thomas
Florjancic Alan
Miyashiro Julie
W Woods Keith
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2013009873A publication Critical patent/MX2013009873A/es
Publication of MX340402B publication Critical patent/MX340402B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere a compuestos de fórmula (I) o sus sales farmacéuticamente aceptables, en donde X, Y, Z, R3 y R4 se definen en la descripción. La presente invención también se refiere a composiciones que contienen dichos compuestos que son útiles para inhibir cinasas tales como wee-1 y métodos de tratamiento de enfermedades como el cáncer.
MX2013009873A 2011-02-28 2012-02-27 Inhibidores triciclicos de cinasas. MX340402B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161447405P 2011-02-28 2011-02-28
PCT/US2012/026685 WO2012161812A1 (en) 2011-02-28 2012-02-27 Tricyclic inhibitors of kinases

Publications (2)

Publication Number Publication Date
MX2013009873A MX2013009873A (es) 2014-03-12
MX340402B true MX340402B (es) 2016-07-07

Family

ID=46000328

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009873A MX340402B (es) 2011-02-28 2012-02-27 Inhibidores triciclicos de cinasas.

Country Status (11)

Country Link
US (1) US8710065B2 (es)
EP (1) EP2681221B1 (es)
JP (1) JP5886326B2 (es)
CN (1) CN103703005A (es)
AR (1) AR085502A1 (es)
CA (1) CA2827648A1 (es)
ES (1) ES2587514T3 (es)
MX (1) MX340402B (es)
TW (1) TWI532742B (es)
UY (1) UY33925A (es)
WO (1) WO2012161812A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
UA117347C2 (uk) 2012-06-13 2018-07-25 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN105263931B (zh) 2013-04-19 2019-01-25 因赛特公司 作为fgfr抑制剂的双环杂环
JPWO2015029447A1 (ja) * 2013-08-30 2017-03-02 興和株式会社 光学活性カルビノール化合物の製造方法
GB201322602D0 (en) * 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
US10300055B2 (en) 2014-04-10 2019-05-28 Dalhousie University Treatment of parkinson's disease through ARFGAP1 inhibition
EP3185860A4 (en) 2014-08-29 2018-08-29 The Board of Regents of the University of Texas System Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
AU2017359844B2 (en) 2016-11-16 2021-09-30 Impact Therapeutics (Shanghai), Inc 8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidine-5(6H)-ketone compound
CN110198943B (zh) * 2017-01-23 2021-04-16 石家庄智康弘仁新药开发有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
EP3600247A1 (en) 2017-03-31 2020-02-05 Seattle Genetics, Inc. Combinations of chk1- and wee1 - inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11345710B2 (en) 2017-07-10 2022-05-31 Impact Therapeutics (Shanghai), Inc Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
US11897867B2 (en) 2017-08-04 2024-02-13 Bayer Aktiengesellschaft 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer
CN107821390A (zh) * 2017-10-13 2018-03-23 南京扬子鸿利源化学品有限责任公司 一种甲基磺草酮油悬浮剂及其制备方法
EP3712150A4 (en) 2017-11-01 2021-03-10 Shijiazhuang Sagacity New Drug Development Co., Ltd. MACROCYCLIC COMPOUND SERVING AS AN INHIBITOR OF WEE1 AND ITS APPLICATIONS
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
CN108727249A (zh) * 2018-07-07 2018-11-02 台州学院 3-二氟甲基哌啶盐酸盐及其衍生物的合成方法
KR20210066839A (ko) * 2018-09-27 2021-06-07 베타 파머수티컬 컴퍼니 리미티드 Fgfr4 저해제 및 그것의 용도
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020083404A1 (zh) 2018-10-26 2020-04-30 南京明德新药研发有限公司 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
CN113784968B (zh) 2019-04-30 2024-03-15 无锡智康弘义生物科技有限公司 Wee1抑制剂化合物的晶型及其应用
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2023509260A (ja) 2019-08-14 2023-03-08 インサイト・コーポレイション Ｃｄｋ２阻害剤としてのイミダゾリルピリミジニルアミン化合物
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
PE20221085A1 (es) 2019-10-14 2022-07-05 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
CN114502559B (zh) * 2019-10-16 2024-02-02 上海瑛派药业有限公司 二氢咪唑并嘧啶并嘧啶酮类化合物
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AU2021290701A1 (en) 2020-06-17 2023-02-02 Wigen Biomedicine Technology (shanghai) Co., Ltd. Pyrazolo(3,4-d)pyrimidine-3-ketone derivative as Wee-1 inhibitor
WO2022174765A1 (zh) * 2021-02-19 2022-08-25 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
EP4332104A1 (en) * 2021-04-30 2024-03-06 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023083194A1 (zh) * 2021-11-09 2023-05-19 杭州格博生物医药有限公司 Wee1蛋白激酶降解剂及其用途
CN116836184A (zh) * 2022-03-25 2023-10-03 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004029293D1 (de) 2003-07-25 2010-11-04 Novartis Ag p-38-Kinasehemmer
US20050070554A1 (en) * 2003-08-27 2005-03-31 Amgen Inc. Substituted heterocyclic compounds and methods of use
US20050250836A1 (en) * 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
AR058277A1 (es) 2005-12-09 2008-01-30 Solvay Pharm Gmbh N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
US8299080B2 (en) * 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
CA2703489A1 (en) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
WO2009151997A1 (en) 2008-06-12 2009-12-17 Merck & Co., Inc. Process for producing bicycloaniline derivatives
CA2745970A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative

Also Published As

Publication number Publication date
CN103703005A (zh) 2014-04-02
TWI532742B (zh) 2016-05-11
EP2681221B1 (en) 2016-05-18
AR085502A1 (es) 2013-10-09
US8710065B2 (en) 2014-04-29
ES2587514T3 (es) 2016-10-25
US20120220572A1 (en) 2012-08-30
JP5886326B2 (ja) 2016-03-16
TW201247675A (en) 2012-12-01
EP2681221A1 (en) 2014-01-08
UY33925A (es) 2012-09-28
MX2013009873A (es) 2014-03-12
CA2827648A1 (en) 2012-11-29
JP2014506929A (ja) 2014-03-20
WO2012161812A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
MX2013009873A (es) Inhibidores triciclicos de cinasas.
PH12017502141A1 (en) Compounds and their methods of use
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
MX361815B (es) Compuestos pirazolopirimidinicos como inhibidores de cinasas.
MX2012013197A (es) Inhibidores de indazol de cinasa.
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
JO2998B1 (ar) مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
UA115983C2 (uk) Інгібітори днк-пк
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
GEP201706688B (en) Cdk8/cdk19 selective inhibitors and their use in anti- metastatic and chemopreventative methods for cancer
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MX363551B (es) Compuestos derivados de pirazina como inhibidores de cinasa.
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
PH12016502133A1 (en) Substituted tricycle compounds as fgfr inhibitors
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази
TR201902034T4 (tr) Kanser hastalıklarının tedavisi için mdm2 inhibitörleri olarak piperidinon türevleri.

Legal Events

Date Code Title Description
FG Grant or registration